News

On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...
Hims & Hers will begin offering generic semaglutide drugs in Canada next year after Novo Nordisk lost its exclusive patent ...
Mr Richard Delali Ahedor, the National President of the Ghana Health Information Management Association (GHIMA), has raised ...
Hims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...
Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the ...
Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.
The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...